PATENT CLAIM ANALYSIS

Application Number: 15874476
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "003800"]

Abstract:
The present invention provides a CXCL12 1  peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Claim (Index 7):
The method of  claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier or diluent.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 86.0
- Lexical Diversity: 1.20513
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14736535', '13115666', '13502893', '12520811', '12255360']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7163613647618559
- 35 USC 102 Novelty (BERT): 0.5905876643442804
- Combined Prediction Score: 0.7037839947200983
- Mean Citation Score: 309.46267400000005
- Max Citation Score: 515.7698
- Similarity Product: 397.0943170782209

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test